|
|
venBio is a life sciences investment firm, partnering with industry leaders to build and invest in game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs. With a presence in San Francisco, CA, venBio manages both a long/ short equity strategy along with venture capital funds which are backed by leading life sciences companies and qualified financial investors. The two venBio strategic funds have invested in 14 companies to date, including: Cytos (now KURN), Aragon (acquired by J&J), Solstice, Labrys (acquired by Teva), Seragon (acquired by Roche/Genentech), Aurinia (AUPH), Heart Metabolics, Metacrine, Alexo, Precision Biosciences, Checkmate, Adheren, Apellis, and Nabriva (NBRV). In May 2016, the firm closed venBio Global Strategic Fund II, its second life sciences venture capital fund, for a total of approximately $315 million, exceeding its target of $250 million. venBio's Strategic Fund II is anchored by major investments from three strategic limited partners - Amgen, Merck, and Baxalta -along with a group of financial Limited Partners. The firm announced (April 2020) the closing of venBio Global Strategic Fund III, its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in capital commitments in an oversubscribed fundraise.
|
